Funding for this research was provided by:
Korean Academy of Medical Sciences
Received: 17 July 2018
Accepted: 7 September 2018
First Online: 14 September 2018
Ethics approval and consent to participate
: The study was approved by Institutional Review Board and Ethics Committee of Hallym University Sacred Heart Hospital (IRB No. 2011-I077) and conducted according to the Declaration of Helsinki. Written informed consent was obtained from all participants.
: Jiyoung Kim has no potential conflicts of interest.Soo-Jin Cho was a site investigator of multicenter trial sponsored by Otsuka Korea, Eli Lilly and Company, Korea BMS, and Parexel Korea Co., Ltd.. Soo-Jin Cho also worked as an advisory member for Teva. Soo-Jin Cho received research support from Hallym University Research Fund 2016 and Academic award of Myung In Pharm. Co. Ltd. Soo-Jin Cho also received lecture honoraria from Yuyu Pharmaceutical Company and Allergan Korea.Won-Joo Kim has no potential conflicts of interest.Kwang Ik Yang has no potential conflicts of interest.Chang-Ho Yun has no potential conflicts of interest.Min Kyung Chu was a site investigator for a multi-center trial sponsored by Otsuka Korea, Novartis International AG and Eli Lilly and Company. Min Kyung Chu worked an advisory member for Teva, and received lecture honoraria from Allergan Korea and Yuyu Pharmaceutical Company in the past 24 months.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.